Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Ighovwerha OfotokunAIDS Clinical Trials Group (ACTG) A5257 Team

Abstract

Metabolic effects following combination antiretroviral therapy (cART) vary by regimen type. Changes in metabolic effects were assessed following cART in the AIDS Clinical Trials Group (ACTG) A5257 study, and correlated with plasma ritonavir trough concentrations (C24). Treatment-naive adult subjects were randomized to ritonavir-boosted atazanavir or darunavir, or raltegravir-based cART. Changes in lipids and other metabolic outcomes over time were estimated. Differences between arms were estimated with 97.5% confidence intervals and compared using pairwise Student t tests. Associations between ritonavir C24 and lipid changes at week 48 were evaluated via linear regression. Analyses included 1797 subjects with baseline fasting data. Baseline lipid profiles and metabolic syndrome rates (approximately 21%) were similar across arms. Comparable increases occurred in total cholesterol, triglycerides, and low-density lipoprotein cholesterol with the boosted protease inhibitors (PIs); each PI had greater increases relative to raltegravir (all P ≤ .001 at week 96). Metabolic syndrome incident rates by week 96 (approximately 22%) were not different across arms. Ritonavir C24 was not different by arm (P = .89) (median, 69 ng/mL and 74 ng/...Continue Reading

References

May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jun 12, 2003·JAMA : the Journal of the American Medical Association·Sharon A RiddlerLawrence A Kingsley
Nov 1, 2003·AIDS Patient Care and STDs·Daniel González de RequenaVincent Soriano
Sep 25, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·David Alain Wohl, Todd T Brown
Sep 17, 2008·AIDS Patient Care and STDs
Apr 21, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jeffrey L LennoxUNKNOWN STARTMRK Investigators
Jul 9, 2010·Lancet·Paul A Volberding, Steven G Deeks
May 6, 2011·BMC Medicine·Eva KassiGeorge Chrousos
Jun 15, 2011·Best Practice & Research. Clinical Endocrinology & Metabolism·Signe W Worm, Jens D Lundgren
Jul 26, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Supriya KrishnanDenise L Jacobson
Jul 13, 2013·The European Respiratory Journal·Ben Michael BrumptonXiao-Mei Mai

❮ Previous
Next ❯

Citations

Oct 2, 2015·Current HIV/AIDS Reports·R Martin-IguacelN Friis-Moller
Jul 30, 2016·The Lancet. HIV·Pere Domingo, Francesc Vidal
Sep 15, 2016·The Journal of Infectious Diseases·Michael L FreemanMichael M Lederman
Mar 28, 2017·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Theodoros KelesidisJudith S Currier
Dec 16, 2017·The Journal of Antimicrobial Chemotherapy·M FloridiaUNKNOWN Italian Group on Surveillance of Antiretroviral Treatment in Pregnancy
Aug 22, 2017·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jamison NorwoodJohn R Koethe
May 24, 2017·Journal of the American Heart Association·Jason V BakerUNKNOWN INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Tre
Dec 5, 2017·Expert Opinion on Drug Safety·Rosa de MiguelJose R Arribas
Jun 25, 2019·Expert Opinion on Pharmacotherapy·Anna Gebhardt, Carl J Fichtenbaum
Dec 4, 2019·Current Opinion in Infectious Diseases·Allison Ross Eckard, Grace A McComsey
Dec 13, 2019·The Journal of Infectious Diseases·Virginia A Triant, Mark J Siedner
Jun 26, 2020·MMW Fortschritte der Medizin·Tim HollsteinUrsula Kassner
Aug 27, 2016·Current HIV/AIDS Reports·Emma Kaplan-LewisMikyung Lee
Jan 5, 2019·Infectious Diseases and Therapy·Berend J van WelzenJoop E Arends
Feb 8, 2020·Current Treatment Options in Infectious Diseases·Lauren F CollinsEmily J Cartwright
Oct 13, 2016·Current Cardiology Reports·Matthew J FeinsteinChristopher T Longenecker
Oct 26, 2018·Mediators of Inflammation·Ana N MonczorJordan E Lake
Jun 12, 2019·Nature Reviews. Cardiology·Priscilla Y Hsue, David D Waters
Feb 6, 2020·Progress in Cardiovascular Diseases·Cemal OzemekCatherine M Jankowski
Jun 3, 2021·Cells·Athanasios-Dimitrios Bakasis, Theodoros Androutsakos
May 29, 2021·Expert Opinion on Drug Safety·Camilla Ingrid HatlebergCaroline Sabin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved